Amyotrophic lateral sclerosis outcome measures and the role of albumin and creatinine: A population-based study

JAMA Neurology

Volumn 71, Issue 9, 2014, Pages 1134-1142

  Chiò, Adriano ^a,b   Calvo, Andrea ^a,b   Bovio, Giacomo ^c   Canosa, Antonio ^a   Bertuzzo, Davide ^a   Galmozzi, Francesco ^a   Cugnasco, Paolo ^a   Clerico, Marinella ^d   De Mercanti, Stefania ^d   Bersano, Enrica ^e   Cammarosano, Stefania ^a   Ilardi, Antonio ^a   Manera, Umberto ^a   Moglia, Cristina ^a   Sideri, Riccardo ^c   Marinou, Kalliopi ^c   Bottacchi, Edo ^f   Pisano, Fabrizio ^c   Cantello, Roberto ^g   Mazzini, Letizia ^e   Mora, Gabriele ^c   more..

^a UNIVERSITY OF TURIN   (Italy)

^b CITTÀ DELLA SALUTE E DELLA SCIENZA HOSPITAL   (Italy)

^c IRCCS   (Italy)

^d SAN LUIGI GONZAGA UNIVERSITY HOSPITAL   (Italy)

^e AISLA Italian Association for Amyotrophic Lateral Sclerosis   (Italy)

^f Aosta Hospital   (Italy)

^g UNIVERSITY OF EASTERN PIEDMONT   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BILIRUBIN; BIOLOGICAL MARKER; CHOLESTEROL; CREATINE KINASE; CREATININE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; THYROTROPIN; URIC ACID; SERUM ALBUMIN;

ADULT; AGED; AMYOTROPHIC LATERAL SCLEROSIS; ARTICLE; BILIRUBIN BLOOD LEVEL; BODY MASS; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CORRELATION ANALYSIS; CREATINE KINASE BLOOD LEVEL; DISEASE COURSE; DISEASE MARKER; DISEASE SEVERITY; ERYTHROCYTE SEDIMENTATION RATE; FAT FREE MASS; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INFLAMMATION; LEUKOCYTE COUNT; LIPOPROTEIN BLOOD LEVEL; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MONOCYTE; MUSCLE ATROPHY; NEUTROPHIL COUNT; OUTCOME ASSESSMENT; POPULATION RESEARCH; PROGNOSIS; PROTEIN FUNCTION; SEX DIFFERENCE; SURVIVAL; TERTIARY CARE CENTER; THYROTROPIN BLOOD LEVEL; URIC ACID BLOOD LEVEL; VALIDATION STUDY; BLOOD; ITALY; MIDDLE AGED; MORTALITY; PATHOLOGY; PREDICTIVE VALUE; SENSITIVITY AND SPECIFICITY; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; AMYOTROPHIC LATERAL SCLEROSIS; BIOLOGICAL MARKERS; COHORT STUDIES; CREATININE; DISEASE PROGRESSION; FEMALE; HUMANS; ITALY; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PREDICTIVE VALUE OF TESTS; PROGNOSIS; SENSITIVITY AND SPECIFICITY; SERUM ALBUMIN;

EID: 84907536724     PISSN: 21686149     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaneurol.2014.1129     Document Type: Article

References (53)

1. Renton AE, Chiò A, Traynor BJ. State of play in amyotrophic lateral sclerosis genetics. Nat Neurosci. 2014;17(1):17-23.
2. Chiò A, Logroscino G, Hardiman O, et al Eurals Consortium. Prognostic factors in ALS: a critical review. Amyotroph Lateral Scler. 2009;10(5-6):310-323.
3. Beghi E, Chiò A, Couratier P, et al Eurals Consortium. The epidemiology and treatment of ALS: focus on the heterogeneity of the disease and critical appraisal of therapeutic trials. Amyotroph Lateral Scler. 2011;12(1):1-10.
4. Chiò A, Calvo A, Moglia C, Mazzini L, Mora G; PARALS study group. Phenotypic heterogeneity of amyotrophic lateral sclerosis: a population based study. J Neurol Neurosurg Psychiatry. 2011;82(7):740-746.
5. Dupuis L, Corcia P, Fergani A, et al. Dyslipidemia is a protective factor in amyotrophic lateral sclerosis. Neurology. 2008;70(13):1004-1009.
6. Dorst J, Kühnlein P, Hendrich C, Kassubek J, Sperfeld AD, Ludolph AC. Patients with elevated triglyceride and cholesterol serum levels have a prolonged survival in amyotrophic lateral sclerosis. J Neurol. 2011;258(4):613-617.
7. Keizman D, Ish-Shalom M, Berliner S, et al. Low uric acid levels in serum of patients with ALS: further evidence for oxidative stress? J Neurol Sci. 2009;285(1-2):95-99.
8. Ikeda K, Hirayama T, Takazawa T, Kawabe K, Iwasaki Y. Relationships between disease progression and serum levels of lipid, urate, creatinine and ferritin in Japanese patients with amyotrophic lateral sclerosis: a cross-sectional study. Intern Med. 2012;51(12):1501-1508.
9. Paillisse C, Lacomblez L, Dib M, Bensimon G, Garcia-Acosta S, Meininger V. Prognostic factors for survival in amyotrophic lateral sclerosis patients treated with riluzole. Amyotroph Lateral Scler Other Motor Neuron Disord. 2005;6(1):37-44.
10. Chiò A, Mora G, Calvo A, Mazzini L, Bottacchi E, Mutani R; PARALS. Epidemiology of ALS in Italy: a 10-year prospective population-based study. Neurology. 2009;72(8):725-731.
11. Brooks BR, Miller RG, Swash M, Munsat TL; World Federation of Neurology Research Group on Motor Neuron Diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1(5):293-299.
12. Cedarbaum JM, Stambler N, Malta E, et al BDNF ALS Study Group (Phase III). The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. J Neurol Sci. 1999;169(1-2):13-21.
13. Chumlea WC, Roche AF, Steinbaugh ML. Estimating stature from knee height for persons 60 to 90 years of age. J Am Geriatr Soc. 1985;33(2):116-120.
14. World Health Organization. Global Database on Body Mass Index. http://apps.who.int/bmi/index.jsp. Published 2013. Accessed January 6, 2014.
15. Chiò A, Calvo A, Mazzini L, et al PARALS. Extensive genetics of ALS: a population-based study in Italy. Neurology. 2012;79(19):1983-1989.
16. Desport JC, Preux PM, Bouteloup-Demange C, et al. Validation of bioelectrical impedance analysis in patients with amyotrophic lateral sclerosis. Am J Clin Nutr. 2003;77(5):1179-1185.
17. Desport JC, Marin B, Funalot B, Preux PM, Couratier P. Phase angle is a prognostic factor for survival in amyotrophic lateral sclerosis. Amyotroph Lateral Scler. 2008;9(5):273-278.
18. Ha CE, Bhagavan NV. Novel insights into the pleiotropic effects of human serum albumin in health and disease. Biochim Biophys Acta. 2013;1830(12):5486-5493.
19. Anraku M, Chuang VT, Maruyama T, Otagiri M. Redox properties of serum albumin. Biochim Biophys Acta. 2013;1830(12):5465-5472.
20. Friedman AN, Fadem SZ. Reassessment of albumin as a nutritional marker in kidney disease. J Am Soc Nephrol. 2010;21(2):223-230.
21. Sacks GS, Dearman K, Replogle WH, Cora VL, Meeks M, Canada T. Use of subjective global assessment to identify nutrition-associated complications and death in geriatric long-term care facility residents. J Am Coll Nutr. 2000;19(5):570-577.
22. Engelman DT, Adams DH, Byrne JG, et al. Impact of body mass index and albumin on morbidity and mortality after cardiac surgery. J Thorac Cardiovasc Surg. 1999;118(5):866-873.
23. Gibbs J, Cull W, Henderson W, Daley J, Hur K, Khuri SF. Preoperative serum albumin level as a predictor of operative mortality and morbidity: results from the National VA Surgical Risk Study. Arch Surg. 1999;134(1):36-42.
24. Obialo CI, Okonofua EC, Nzerue MC, Tayade AS, Riley LJ. Role of hypoalbuminemia and hypocholesterolemia as copredictors of mortality in acute renal failure. Kidney Int. 1999;56(3):1058-1063.
25. Chima CS, Barco K, Dewitt ML, Maeda M, Teran JC, Mullen KD. Relationship of nutritional status to length of stay, hospital costs, and discharge status of patients hospitalized in the medicine service. J Am Diet Assoc. 1997;97(9):975-978, quiz 979-980.
26. Gupta D, Lis CG. Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature. Nutr J. 2010;9:69.
27. Barbosa-Silva MC. Subjective and objective nutritional assessment methods: what do they really assess? Curr Opin Clin Nutr Metab Care. 2008;11(3):248-254.
28. Ghasemzadeh N, Nyberg F, Hjertén S. Highly selective artificial gel antibodies for detection and quantification of biomarkers in clinical samples: albumin in body fluids of patients with neurological disorders. J Sep Sci. 2008;31(22):3954-3958.
29. Yang JW, Kim SM, Kim HJ, et al. Hypolipidemia in patients with amyotrophic lateral sclerosis: a possible gender difference? J Clin Neurol. 2013;9(2):125-129.
30. Keizman D, Rogowski O, Berliner S, et al. Low-grade systemic inflammation in patients with amyotrophic lateral sclerosis. Acta Neurol Scand. 2009;119(6):383-389.
31. Patel SS, Molnar MZ, Tayek JA, et al. Serum creatinine as a marker of muscle mass in chronic kidney disease: results of a cross-sectional study and review of literature. J Cachexia Sarcopenia Muscle. 2013;4(1):19-29.
32. Viollet L, Gailey S, Thornton DJ, et al. Utility of cystatin C to monitor renal function in Duchenne muscular dystrophy. Muscle Nerve. 2009;40(3):438-442.
33. Baxmann AC, Ahmed MS, Marques NC, et al. Influence of muscle mass and physical activity on serum and urinary creatinine and serum cystatin C. Clin J Am Soc Nephrol. 2008;3(2):348-354.
34. Swaminathan R, Ho CS, Chu LM, Donnan S. Relation between plasma creatinine and body size. Clin Chem. 1986;32(2):371-373.
35. Sala A, Tarnopolsky M, Webber C, Norman G, Barr R. Serum creatinine: a surrogate measurement of lean body mass in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2005;45(1):16-19.
36. Hashizume A, Katsuno M, Banno H, et al. Longitudinal changes of outcome measures in spinal and bulbar muscular atrophy. Brain. 2012;135 (pt 9):2838-2848.
37. Desport JC, Preux PM, Truong TC, Vallat JM, Sautereau D, Couratier P. Nutritional status is a prognostic factor for survival in ALS patients. Neurology. 1999;53(5):1059-1063.
38. Chiò A, Mora G, Leone M, et al; Piemonte and Valle d'Aosta Register for ALS (PARALS). Early symptom progression rate is related to ALS outcome: a prospective population-based study. Neurology. 2002;59(1):99-103.
39. Kimura F, Fujimura C, Ishida S, et al. Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology. 2006;66(2):265-267.
40. Reich-Slotky R, Andrews J, Cheng B, et al. Body mass index (BMI) as predictor of ALSFRS-R score decline in ALS patients. Amyotroph Lateral Scler Frontotemporal Degener. 2013;14(3):212-216.
41. Marin B, Desport JC, Kajeu P, et al. Alteration of nutritional status at diagnosis is a prognostic factor for survival of amyotrophic lateral sclerosis patients. J Neurol Neurosurg Psychiatry. 2011;82(6):628-634.
42. Chiò A, Calvo A, Ilardi A, et al. Lower serum lipid levels are related to respiratory impairment in patients with ALS. Neurology. 2009;73(20):1681-1685.
43. Paganoni S, Zhang M, Quiroz Zárate A, et al. Uric acid levels predict survival in men with amyotrophic lateral sclerosis. J Neurol. 2012;259(9):1923-1928.
44. Sutedja NA, van der Schouw YT, Fischer K, et al. Beneficial vascular risk profile is associated with amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2011;82(6):638-642.
45. Huisman MH, de Jong SW, Verwijs MC, et al. Family history of neurodegenerative and vascular diseases in ALS: a population-based study. Neurology. 2011;77(14):1363-1369.
46. Ames BN, Cathcart R, Schwiers E, Hochstein P. Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. Proc Natl Acad Sci U S A. 1981;78(11):6858-6862.
47. Bowman GL, Shannon J, Frei B, Kaye JA, Quinn JF. Uric acid as a CNS antioxidant. J Alzheimers Dis. 2010;19(4):1331-1336.
48. Schwarzschild MA, Schwid SR, Marek K, et al Parkinson Study Group PRECEPT Investigators. Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol. 2008;65(6):716-723.
49. Ascherio A, Le Witt PA, Xu K, et al Parkinson Study Group DATATOP Investigators. Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol. 2009;66(12):1460-1468.
50. Auinger P, Kieburtz K, McDermott MP. The relationship between uric acid levels and Huntington's disease progression. Mov Disord. 2010;25(2):224-228.
51. Lee JE, Song SK, Sohn YH, Lee PH. Uric acid as a potential disease modifier in patients with multiple system atrophy. Mov Disord. 2011;26(8):1533-1536.
52. Irizarry MC, Jin S, He F, et al. Incidence of new-onset seizures in mild to moderate Alzheimer disease. Arch Neurol. 2012;69(3):368-372.
53. Zoccolella S, Simone IL, Capozzo R, et al. An exploratory study of serum urate levels in patients with amyotrophic lateral sclerosis. J Neurol. 2011; 258(2):238-243.